Get all premium features to the best stock analysis tool

Continues to deliver record revenue and improving operating metrics Significant expansion in the United States underway, with NOOR and other Sky Premium Life products expected to drive strong profitability supported by gross margins of approximately 75% NOOR Collagen alone is projected to generate more than $12 million in annualized revenue Strong growth expected ahead, driven by organic progress and M&A pipeline including a recent LOI to acquire an $11.5 million pharmacy distribution network Holds valuable non-core strategic real estate and digital assets with an estimated fair market value exceeding $18 million, providing meaningful balance sheet flexibility Evaluating potential monetization of non-core assets to support more efficient capital allocation accelerate strategic investments address the current valuation disconnect, including options such as share repurchases Recent geopolitical turmoil has had a negligible impact on the Company's operations, with record-breaking growth continuing at a strong pace To issue guidance update following the release of fourth quarter and full-year 2025 results Analyst coverage initiated by Zacks Small-Cap Research with a valuation of $4.50 per share CHICAGO, March 19, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today provided a corporate update and announced that it intends to issue updated operational, strategic, and financial guidance following the release of its fourth quarter and full-year 2025 financial results. Record Operating Momentum Cosmos Health continues to deliver record revenue and gross profit while improving operating metrics, reflecting disciplined execution across all core divisions.

CHICAGO, March 11, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”)  (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the purchase of $600,000 of Bitcoin as part of its ongoing digital assets treasury initiative. Following this purchase, Cosmos Health's total investment in digital assets has reached $3.1 million, reflecting the combined value of its holdings in Bitcoin and Ethereum.

CHICAGO, Ill., March 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has entered into a Letter of Intent (“LOI”), through its wholly owned subsidiary CosmoFarm S.A.

CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the appointment of Dr. Dimitrios Iliopoulos to its Advisory Board, where he will support the Company's biotechnology initiatives, with a focus on AI-driven drug discovery and clinical-stage therapeutic development.

The estimated fair market value of the Company's real estate assets is approx $15 million, exceeding the current market cap of approx $13.5 million.

CHICAGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced continued expansion of its United Kingdom (UK) retail footprint as its antimicrobial skin cleanser, C-Scrub Wash Chlorhexidine 4% (“C-Scrub”), is now available through Superdrug , the UK's second-largest beauty and health retailer. Established over 60 years ago, Superdrug is widely recognized for its leadership in health, wellness, and personal care categories and operates more than 830 stores across the UK and the Republic of Ireland, including over 200 in-store pharmacies and a growing number of health clinics, complemented by a strong online e-commerce platform.

CHICAGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”)  (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced a significant expansion of its United Kingdom (UK) retail footprint as its antimicrobial skin cleanser, C-Scrub Wash Chlorhexidine 4% (“C-Scrub”), is now available through Tesco , the UK's largest retailer. Tesco is a leading multinational retail group operating across multiple markets and ranked among the top 20 retailers globally , generating over $80 billion in annual revenue.